{
    "organizations": [],
    "uuid": "190725bfddc61765b8e524341fd7be5892f5bd96",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ligand-pharma-to-receive-total-pot/brief-ligand-pharma-to-receive-total-potential-license-milestone-payments-of-up-to-533-8-mln-per-agreement-with-roivant-idUSFWN1QO0QA",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS - PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MILLION\n* LIGAND PHARMACEUTICALS SAYS NOW ANTICIPATES 2018 TOTAL REVENUE TO BE APPROXIMATELY $184 MILLION - SEC FILING Source text: ( bit.ly/2FuuOFX ) Further company coverage:\n ",
    "published": "2018-03-07T05:59:00.000+02:00",
    "crawled": "2018-03-07T19:20:33.025+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "pharmaceutical",
        "per",
        "term",
        "license",
        "agreement",
        "roivant",
        "co",
        "receive",
        "total",
        "potential",
        "license",
        "milestone",
        "payment",
        "million",
        "ligand",
        "pharmaceutical",
        "say",
        "anticipates",
        "total",
        "revenue",
        "approximately",
        "million",
        "sec",
        "filing",
        "source",
        "text",
        "company",
        "coverage"
    ]
}